Abstract Number: 2557 • 2017 ACR/ARHP Annual Meeting
Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not?
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of people with psoriasis. The current understanding of these diseases involves patients who…Abstract Number: 2558 • 2017 ACR/ARHP Annual Meeting
DNA Methylation-Dependent Regulation of Cathepsin E Gene Expression By the Transcription Factor Kaiso in MRL/Lpr Mice
Background/Purpose: To identify new candidate genes regulated by DNA methylation and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated genome-wide DNA methylation…Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…Abstract Number: 2560 • 2017 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase Inhibition Reveals Immune Cell Subsets of Diseased NZB/W F1 Mice That Are Reflected in Systemic Lupus Erythematosus Patient Peripheral Blood Mononuclear Cells
Background/Purpose: Spleen tyrosine kinase (SYK) is a driver of B cell receptor and Fc receptor signaling pathways, which have central roles in initiating and driving…Abstract Number: 2561 • 2017 ACR/ARHP Annual Meeting
BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis
Background/Purpose: Bruton's tyrosine kinase (BTK) plays an important role in B cell and FcR mediated myeloid cell activation. We recently described a selective BTK inhibitor,…Abstract Number: 2562 • 2017 ACR/ARHP Annual Meeting
Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling in hematopoietic cells important in the initiation and progression of systemic lupus erythematosus (SLE), including those from…Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…Abstract Number: 2564 • 2017 ACR/ARHP Annual Meeting
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Background/Purpose: Neutrophils are potential instigators of autoimmunity and effectors of organ damage in lupus. However, there is presently no consensus as to whether inhibition of…Abstract Number: 2565 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in Ra and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib
Background/Purpose: Bruton’s tyrosine kinase (BTK) is a clinically-proven target in several hematological indications. Due to its role in mediating the signaling of both B cell…Abstract Number: 2566 • 2017 ACR/ARHP Annual Meeting
Myxomavirus-Derived Serpin (Serp-1) Reduces Diffuse Alveolar Hemorrhage in a Murine Model of Lupus
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an unusual complication of lupus with over 50% mortality. In both humans and mice, DAH is associated with ANCA-negative…Abstract Number: 2567 • 2017 ACR/ARHP Annual Meeting
Type I IFN Blockade Restores Normal Transitional B Cell Development Post-Anti-CD20 Depletion
Background/Purpose: Application of B cell depletion therapy (BCDT) for treatment of SLE has shown promise in some patients, but some patients exhibit disease relapses. Anti-type…Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting
Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…Abstract Number: 2569 • 2017 ACR/ARHP Annual Meeting
Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Cell Function and Its Selective Deficiency in T Lymphocytes Leads to Autoimmunity and Lupus-like Nephritis
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling including a reduced expression of the CD3 zeta signaling chain, and…Abstract Number: 2570 • 2017 ACR/ARHP Annual Meeting
The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus
Background/Purpose: Infiltrating macrophages are one of the hallmarks of renal inflammation and kidney damage in lupus nephritis. Increasing evidence suggests the crucial role of cell-specific…Abstract Number: 2571 • 2017 ACR/ARHP Annual Meeting
IL23 Deficiency Alters Thymic Selection in Lupus Prone Mice
Background/Purpose: We have previously reported that IL-23 receptor deficiency in MRL.lpr mice ameliorates lupus by altering the balance of pro- and anti-inflammatory cytokines in secondary…
ACR Meeting Abstracts